Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Average Price Target from Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.57.

A number of analysts have recently commented on MRSN shares. Citigroup started coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $4.00 price objective (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday, January 10th. Finally, William Blair started coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating on the stock.

Institutional Trading of Mersana Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRSN. Novo Holdings A S bought a new stake in Mersana Therapeutics during the fourth quarter worth $6,078,000. Boxer Capital Management LLC bought a new stake in Mersana Therapeutics during the fourth quarter worth $3,768,000. Verition Fund Management LLC raised its position in Mersana Therapeutics by 11,695.2% during the third quarter. Verition Fund Management LLC now owns 1,303,249 shares of the company’s stock worth $2,463,000 after acquiring an additional 1,292,200 shares in the last quarter. Exome Asset Management LLC bought a new stake in Mersana Therapeutics during the third quarter worth $2,227,000. Finally, 683 Capital Management LLC increased its holdings in shares of Mersana Therapeutics by 392.4% in the fourth quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $1,287,000 after purchasing an additional 717,207 shares during the last quarter. 93.92% of the stock is owned by institutional investors.

Mersana Therapeutics Stock Performance

Shares of MRSN stock opened at $0.58 on Friday. The company’s fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.62. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The firm has a market cap of $71.99 million, a PE ratio of -0.96 and a beta of 1.39. Mersana Therapeutics has a 12 month low of $0.49 and a 12 month high of $6.28.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.